Shares of Corcept Therapeutics Inc. (NASDAQ:CORT) were down 1.1% during mid-day trading on Thursday . The company traded as low as $5.57 and last traded at $5.63, with a volume of 165,811 shares traded. The stock had previously closed at $5.69.

CORT has been the topic of a number of research analyst reports. FBR & Co reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Thursday, August 4th. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th.

The company’s 50-day moving average is $5.80 and its 200-day moving average is $4.98. The firm has a market capitalization of $611.58 million and a price-to-earnings ratio of 614.44.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, August 2nd. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.02. The business earned $19.70 million during the quarter, compared to the consensus estimate of $18.36 million. On average, equities research analysts anticipate that Corcept Therapeutics Inc. will post $0.05 earnings per share for the current fiscal year.

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.